AVEO - AVEO Pharmaceuticals, Inc.
| Previous Close | 1.9600 |
| Open | 1.9200 |
| Bid | 1.92 x 4000 |
| Ask | 1.93 x 3000 |
| Day's Range | 1.8900 - 1.9500 |
| 52 Week Range | 1.4000 - 3.5900 |
| Volume | 389,253 |
| Avg. Volume | 2,437,607 |
| Market Cap | 308.413M |
| Beta (3Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- MarketWatch•yesterday
How to spot risky biotech companies and six to avoid now
With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.
- Motley Fool•8 days ago
Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
- Business Wire•16 days ago
AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
- Business Wire•16 days ago
AVEO Oncology to Present TIVO-3 Data at the 2019 ASCO Genitourinary Cancers Symposium
AVEO Oncology (AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium being held February 14-16, 2019 in San Francisco. It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications.1,2 Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models3, and has demonstrated synergy in combination with nivolumab (anti PD-1) in a Phase 2 study in RCC.
- ACCESSWIRE•23 days ago
4 Pharma Stocks Heating Up On Wednesday (12/26/18)
Premier Health Group (PHGRF) (PHGI), ArQule, Inc (ARQL), Amarin Corporation plc (AMRN), and AVEO Pharmaceuticals, Inc (AVEO) are 4 pharma stocks that may be worth keeping tabs on this week. Premier Health Group (PHGRF) (PHGI) is a company determined to improve the quality of care currently made available to consumers in the primary healthcare space. As an industry leader, the Company is focused on developing proprietary technologies to develop healthcare through a network of interconnected primary care clinics by way of artificial intelligence integration and telemedical advancements.
- Insider Monkey•28 days ago
Is AVEO Pharmaceuticals, Inc. (AVEO) A Good Stock To Buy?
“Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]
- Zacks•29 days ago
Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
- Zacks•last month
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
- Business Wire•last month
AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca
AVEO Oncology (AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI® (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) in first-line hepatocellular carcinoma (HCC), or liver cancer, in a Phase 1/2 study. AVEO will serve as the study sponsor, with study costs shared equally by both parties and clinical drug supplied by each respective company. “We are thrilled to collaborate with AstraZeneca to explore another tivozanib-immunotherapy combination and look forward to understanding the potential of combining tivozanib with durvalumab in liver cancer,” said Michael Bailey, president and chief executive officer of AVEO.
- Motley Fool•last month
Why AVEO Pharmaceuticals Stock Tanked Last Month
The company's meager cash position is worrying investors.
- Business Wire•last month
AVEO Oncology Announces Extension of Debt Facility Interest Only Period
AVEO Oncology (AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined requirements under the agreement, including successfully meeting the primary endpoint of the Company’s Phase 3 TIVO-3 study of tivozanib in refractory advanced or metastatic renal cell carcinoma (RCC), by demonstrating a significant improvement in progression free survival. The Company will begin making principal payments on the $20.0 million facility starting on August 1, 2019.
- TheStreet.com•2 months ago
2 Small Biotech Stocks That Insiders Are Buying
The biotech sector continues to see bearish sentiment and trading action. Small biotech stocks rallied just over 2% on Monday to begin a new trading week, but all those gains were given right back in Tuesday's session.
- GlobeNewswire•2 months ago
New Research Coverage Highlights AVEO Pharmaceuticals, GMS, R1 RCM, Installed Building Products, Stoneridge, and Chicago Rivet & Machine — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- American City Business Journals•2 months ago
Former Aveo CFO misled biotech's investors, jury finds
The SEC accused David Johnston of failing to disclose that the FDA had recommended that Aveo conduct a second late-stage trial of a kidney cancer drug, which was ultimately rejected.
- Zacks•2 months ago
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
- ACCESSWIRE•2 months ago
4 Healthcare Stocks You Should Get To Know Before 2019
New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.
- Business Wire•2 months ago
AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com.
- Business Wire•2 months ago
AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
AVEO Oncology (AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC.
- ACCESSWIRE•2 months ago
Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...
- Zacks•2 months ago
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
- Zacks•2 months ago
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 262.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
AVEO: 3Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 18 cents. Losses, adjusted for non-recurring costs, were 5 cents per share. The results beat Wall Street expectations. ...
- Business Wire•2 months ago
AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the third quarter ended September 30, 2018 and provided a business update.
- Business Wire•2 months ago
AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
AVEO Oncology (AVEO) today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC). The trial met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS). Among these, approximately 26% of patients received checkpoint inhibitor therapy in earlier lines of treatment.
- Zacks•3 months ago
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
